International Clinical Trial: Efficacy and Safety of Gemcitabine Combined with Toripalimab in Docetaxel-Refractory or -Intolerant Patients with Metastatic Castration-Resistant Prostate Cancer: A Prospective, Open-Label, Single-Arm Interventional Study

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115002) titled 'Efficacy and Safety of Gemcitabine Combined with Toripalimab in Docetaxel-Refractory or -Intolerant Patients with Metastatic Castration-Resistant Prostate Cancer: A Prospective, Open-Label, Single-Arm Interventional Study' on Dec. 19, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Condition: Prostate Cancer

Intervention: Trial group:1. Gemcitabine: 1000 mg/m^2, administered via intravenous infusion on Day 1 and Day 8 of each 21-day cycle, with a maximum duration of 8 cycles. Dose adjustment: It is recomme...